Merck & Co. Inc. has announced that the European Commission has approved a new subcutaneous (SC) form of KEYTRUDA® (pembrolizumab) for all adult indications previously approved in the European Union. This marks the first and only subcutaneous immune checkpoint inhibitor available in Europe, which can be administered by a healthcare provider in as little as one minute. The approval covers all 27 EU member states, as well as Iceland, Liechtenstein, and Norway. The new formulation, KEYTRUDA SC™, combines pembrolizumab with berahyaluronidase alfa, a variant of human hyaluronidase developed by Alteogen Inc. The timing of commercial availability will depend on national reimbursement processes in individual countries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251119081276) on November 19, 2025, and is solely responsible for the information contained therein.